Biotechnology APAC News & Press Release Distribution

Biotechnology

All
Global

CU Medicine invents a non-invasive technology for people with uninvestigated bowel symptoms

HONG KONG, Dec. 4, 2024 /PRNewswire/ -- The Chinese University of Hong Kong's Faculty of Medicine (CU Medicine) has, for the first time, discovered novel microbial signatures associated with inflammation of the gastrointestinal (GI) tract and transformed such signatures into clinically applicable...

2024-12-04 22:26 1750

CU Medicine invents a non-invasive technology for people with uninvestigated bowel symptoms

Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

SAN FRANCISCO, U.S. and SUZHOU, China, Dec. 4, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoi...

2024-12-04 08:00 2111

Turn Biotechnologies Announces Landmark Study to Assess Effectiveness of ERA™ Therapy in Restoring Bone Marrow

Researchers from Children's Hospital of Philadelphia (CHOP) seek to expand treatment access for patients MOUNTAIN VIEW, Calif., Dec. 3, 2024 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation and restoration company developing novel mRNA medicines for untreatable, age-related conditions, ...

2024-12-03 22:00 1297

Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Hong Kong

SHANGHAI, Dec. 2, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that Department of Health of the Gover...

2024-12-02 07:40 1636

CBC Group Completes Strategic Acquisition of UCB's Mature Product Portfolio in China

* CBC Group and Mubadala acquire UCB's mature neurology and allergy business inChina for US$680 million. * New company is named NeuroGen Pharma, led by an experienced management team with a strong track record in the biopharma industry. * Strategic acquisition under CBC's buyout strategy exp...

2024-11-30 09:00 5541

Microbio Appoints Paul Brennan as Chair of the Board

BRISBANE, Australia, Nov. 29, 2024 /PRNewswire/ -- Microbio Ltd, the Australian pathogen diagnostics company specialising in innovative molecular diagnostic solutions, has appointedPaul Brennan as Chair of the Board, effective 2nd December 2024. Paul brings extensive global experience as a Non-E...

2024-11-29 06:30 1831

Lanchi Ventures Leads $42M Series A Financing for Allink Biotherapeutics to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. BEIJING, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecific...

2024-11-28 21:30 3062

First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients

MELBOURNE, Australia, Nov. 28, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and Grand Pharmaceutical Group Limited (00512.HK, Grand Pharma) today announce that a first patient has been dosed in the Phase III ZIRCON-CP trial of TLX250-CDx positron ...

2024-11-28 17:22 2051

New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List

ROCKVILLE, Md. and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that the new indication...

2024-11-28 16:59 2077

Everest Medicines Announces NEFECON®, the World's First Approved Treatment for IgA Nephropathy, is Included in China's National Reimbursement Drug List

SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that NEFECON® has been included in the...

2024-11-28 13:43 1773

Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country

SHANGHAI and HONG KONG, Nov. 28, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hema...

2024-11-28 13:04 1878

Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List

SAN FRANCISCO and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2024-11-28 12:07 2169

Everest Medicines to Hold Investor Calls on Data Results from EVER001 Phase 1b/2a Clinical Study in Primary Membranous Nephropathy

SHANGHAI, Nov. 27, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will hold investor calls on t...

2024-11-27 19:08 2674

Kelun-Biotech's TROP2 ADC Sacituzumab tirumotecan (sac-TMT) Approved For Marketing By NMPA Of China For 2L+ Advanced or Metastatic TNBC

CHENGDU, China, Nov. 27, 2024 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization inChina from National Medical Products Administration (NMPA) for the first domestically developed trophoblast cell-surface an...

2024-11-27 14:34 1993

Exyte Receives Micron's Outstanding Supplier Performance Award in Supplier Diversity

STUTTGART, Germany, Nov. 26, 2024 /PRNewswire/ -- Exyte, a global leader in the design, engineering, and delivery of high-tech facilities, was presented with the Outstanding Supplier Performance Award in Supplier Diversity at the Micron Supplier Day 2024. The event, held inSan Francisco, CA, USA,...

2024-11-26 20:19 1215

Exyte Receives Micron's Outstanding Supplier Performance Award in Supplier Diversity

QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology

SINGAPORE, Nov. 26, 2024 /PRNewswire/ -- QDX proudly announces that the team led by its co-founder, Associate ProfessorGiuseppe Barca, has been honoured with the 2024 ACM Gordon Bell Prize, often referred to as the "Nobel Prize of high-performance computing." This accolade recognizes their ground...

2024-11-26 18:49 8648

Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU® (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

* Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC. * Updated results of elacestrant in combination with abemaciclib show favorable efficacy regardless of theESR1 mutation status, with a manageable and predictable safet...

2024-11-26 17:16 1758

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

ROCKVILLE, Md. and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed M...

2024-11-25 08:37 2285

Innovent to Present Clinical Data of Multiple Novel Molecules at ESMO Asia 2024

SAN FRANCISCO and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2024-11-25 08:30 2185

ArkBio Announces Successful Completion of Enrollment and Dosing for Phase 1 Clinical Study of AK0610, a Preventive Antibody Against Respiratory Syncytial Virus Infection

SHANGHAI, Nov. 25, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced today the successful enrollment and dosing of all participants in a Phase 1 clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infec...

2024-11-25 08:18 1822

1 2 345 6 7 ... 180